LTX-03
Pain (Hydrocodone/Acetaminophen abuse-deterrent formulation)
Key Facts
About Acura Pharmaceuticals
Acura Pharmaceuticals is a U.S.-based public company developing and licensing abuse-deterrent drug delivery technologies. Its core business revolves around three proprietary platforms: LIMITX™ for limiting release upon oral overdose, AVERSION® for deterring snorting and injection of opioids, and IMPEDE® for hindering the extraction of pseudoephedrine for methamphetamine production. The company has transitioned to a licensing model, with its lead LIMITX™ candidate (LTX-03) partnered with Abuse Deterrent Pharmaceuticals, while its AVERSION® and IMPEDE® technologies are already commercialized through partnerships with Zyla Life Sciences (OXAYDO®) and MainPointe Pharmaceuticals (Nexafed®), respectively. Acura's strategy targets the significant public health need and regulatory push for safer pain and cold medications.
View full company profile